AVEO Pharmaceuticals, Inc. (AVEO) News

AVEO Pharmaceuticals, Inc. (AVEO): $15.00

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AVEO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 400

in industry

Filter AVEO News Items

AVEO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AVEO News Highlights

  • For AVEO, its 30 day story count is now at 6.
  • Over the past 21 days, the trend for AVEO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about AVEO are BIO, CABA and FUL.

Latest AVEO News From Around the Web

Below are the latest news stories about AVEO PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AVEO as an investment opportunity.

LG Chem Completes Acquisition of AVEO Oncology

AVEO to Become the U.S. Foundation for LG Chem Life Sciences’ Oncology DivisionSEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, in an all-cash transaction with an implied equity value of $571M on a ful

Yahoo | January 19, 2023

AVEO Oncology Stockholders Approve Acquisition by LG Chem

BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders (the “Special Meeting”) held today, AVEO stockholders approved the adoption of the Agreement and Plan of Merger among LG Chem, Ltd. (“LG Chem”), a subsidiary of LG Chem and AVEO (the “merger agreement”). As previously

Yahoo | January 6, 2023

AVEO Oncology Reminds Stockholders to Vote “FOR” All-Cash Transaction with LG Chem in advance of the Special Meeting of Stockholders

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend that AVEO Stockholders Vote “FOR” the TransactionBOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO’s Special Meeting of Stockholders (the “Special Meeting”) “FOR” the adoption of the Agreement and P

Yahoo | January 3, 2023

The Zacks Analyst Blog Highlights AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences

AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences are included in this Analyst Blog.

Yahoo | January 3, 2023

4 Drug Stocks That More Than Doubled This Year

We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.

Yahoo | December 30, 2022

12 Best Performing Biotech Stocks in 2022

In this article, we discuss 12 best performing biotech stocks in 2022. If you want to see more stocks in this selection, check out 5 Best Performing Biotech Stocks in 2022. Fitch Ratings has assigned a Neutral rating to the global pharmaceutical and biotech industry, which indicates the assumption of a collaborative operating backdrop in […]

Yahoo | December 29, 2022

Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?

Here is how AVEO Pharmaceuticals (AVEO) and Merit Medical (MMSI) have performed compared to their sector so far this year.

Yahoo | December 26, 2022

Is Basilea Pharmaceutica (BPMUF) Outperforming Other Medical Stocks This Year?

Here is how Basilea Pharmaceutica AG (BPMUF) and AVEO Pharmaceuticals (AVEO) have performed compared to their sector so far this year.

Yahoo | December 9, 2022

uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy

uniQure (QURE) shares rise after its partner CSL Limited received FDA nod for one-time gene therapy, Hemgenix, for treating adults with Hemophilia B.

Yahoo | November 23, 2022

Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track Designation

Palisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal (GI) surgery.

Yahoo | November 23, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5666 seconds.